Clinical Trials
3-D Matrix is selling its approved hemostatic agent PuraStat® in Europe, Latin America and Southeast Asia and preparing investigational studies for FDA approval. In the United States, 3-D Matrix has successfully completed a pilot study to use PuraMatrix® as a dental bone void filler. In Japan 3-D Matrix is currently completing trials for various clinical applications.
PuraMatrix® is a platform technology that can fulfill numerous clinical indications and therapeutic needs.
Hemostasis
PuraStat® has completed a successful clinical trial in Japan. A clinical trial is being planned in the United States for PMA approval, and in Europe as post-marketing clinical follow-up studies
News
Find out the most recent developments at 3-D Matrix
Collaborations
Learn how PuraMatrix® can enhance your technology
Publications
Review the strong body of literature utilizing PuraMatrix®